title: Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D002017:Budgets; D016527:Drug Costs; D004469:Economics, Hospital; D017048:Health Care Costs; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000453:epidemiology*; D018358:Neuroendocrine Tumors / Q000188:drug therapy / Q000453:epidemiology*; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000453:epidemiology*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000191:economics* / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000453:epidemiology*; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D013004:Somatostatin